8-K
filed May 26, 2023, 7:59 PM ET
ticker TMDX
CIK 0001756262
other material
confidence high
sentiment neutral
materiality 0.50
Shareholders approve amended equity plan, adding 1M shares and extending to 2033
TransMedics Group, Inc.
- Plan amendment increases share reserve by 1,000,000 shares and extends expiration to June 1, 2033.
- Directors elected: Waleed H. Hassanein, James R. Tobin, Edward M. Basile, Thomas J. Gunderson, Edwin M. Kania, Stephanie Lovell, Merilee Raines, David Weill.
- Say-on-pay proposal approved with 22,963,086 votes for, 1,519,849 against.
- Plan amendment approved with 19,996,361 votes for, 4,483,557 against.
- Ratification of PricewaterhouseCoopers as auditor passed with 26,378,751 votes for.
Key facts
Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
TransMedics Group, Inc. shareholders approved Approval of Amended and Restated TransMedics Group, Inc. 2019 Stock Incentive Plan at the 2023-05-25 meeting.
- Proposal
- equity plan
- Outcome
- passed
- Meeting
- 2023-05-25
Exact text from the filing
Proposal Three : The shareholders approved the Amended and Restated TransMedics Group, Inc. 2019 Stock Incentive Plan, based on the following votes: For Against Abstain Broker Non-Votes 19,996,361 4,483,557 21,292 2,433,153
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
TransMedics Group, Inc. shareholders approved Election of eight directors to serve until the 2024 annual meeting at the 2023-05-25 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2023-05-25
Exact text from the filing
Proposal One : The shareholders elected Waleed H. Hassanein, M.D., James R. Tobin, Edward M. Basile, Thomas J. Gunderson, Edwin M. Kania, Stephanie Lovell, Merilee Raines and David Weill, M.D. as directors, each to serve on the board of directors of the Company until the 2024 annual meeting of the Company’s shareholders to be held in 2024 or until his or her successor is duly elected and qualified in accordance with our restated articles of organization and second amended and restated bylaws, or his or her earlier death, resignation or removal, based on the following votes: Director Nominee For Against Abstain Broker Non-Votes Waleed H. Hassanein, M.D 24,276,377 218,114 6,719 2,433,153 James R. Tobin 22,266,327 2,227,909 6,974 2,433,153 Edward M. Basile 19,270,950 5,222,893 7,367 2,433,153 Thomas J. Gunderson 24,375,647 118,498 7,065 2,433,153 Edwin M. Kania 24,144,520 349,634 7,056 2,433,153 Stephanie Lovell 23,196,175 1,298,370 6,665 2,433,153 Merilee Raines 24,372,323 122,126 6,761
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
TransMedics Group, Inc. shareholders approved Ratification of PricewaterhouseCoopers LLP as independent auditor for fiscal year ending December 31, 2023 at the 2023-05-25 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2023-05-25
Exact text from the filing
Proposal Four : The shareholders ratified the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for its fiscal year ending December 31, 2023, based on the following votes: For Against Abstain 26,378,751 546,315 9,297
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
TransMedics Group, Inc. shareholders approved Advisory vote on executive compensation at the 2023-05-25 meeting.
- Proposal
- say on pay
- Outcome
- passed
- Meeting
- 2023-05-25
Exact text from the filing
Proposal Two : The shareholders approved, on a non-binding advisory basis, the compensation paid to the Company’s named executive officers, based on the following votes: For Against Abstain Broker Non-Votes 22,963,086 1,519,849 18,275 2,433,153
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.